Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Operating Leases (2019 - 2025)

Benitec Biopharma's Operating Leases history spans 5 years, with the latest figure at $284000.0 for Q2 2024.

  • For Q2 2024, Operating Leases changed 0.0% year-over-year to $284000.0; the TTM value through Jun 2024 reached $284000.0, changed 0.0%, while the annual FY2024 figure was $284000.0, 0.0% changed from the prior year.
  • Operating Leases for Q2 2024 was $284000.0 at Benitec Biopharma, down from $354000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $954000.0 in Q3 2021 and bottomed at $108000.0 in Q4 2020.
  • The 5-year median for Operating Leases is $356500.0 (2020), against an average of $442428.6.
  • The largest annual shift saw Operating Leases skyrocketed 546.3% in 2021 before it crashed 64.98% in 2023.
  • A 5-year view of Operating Leases shows it stood at $108000.0 in 2020, then surged by 546.3% to $698000.0 in 2021, then dropped by 1.86% to $685000.0 in 2022, then plummeted by 38.25% to $423000.0 in 2023, then plummeted by 32.86% to $284000.0 in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Operating Leases are $284000.0 (Q2 2024), $354000.0 (Q1 2024), and $423000.0 (Q4 2023).